Myasthenia Gravis Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Surgery, Medication, and Others), By End User (Hospitals, Clinics, and Others) and Region Forecast 2020-2031

Myasthenia Gravis Market size was valued at US$ 1.4 billion in 2024 and is expected to reach US$ 1.9 billion by 2031, growing at a significant CAGR of 5.0% from 2025-2031. Myasthenia gravis is an autoimmune disease diagnosis, which means the immune system, which normally protects the body from foreign organisms, misguidedly attacks itself. MG which is an antibody-mediated autoimmune disease is a rare neurological disease. Myasthenia gravis is caused by a failure in the spread of nerve impulses to muscles. As per the National Center for Biotechnology Information (NCBI), the prevalence rate for Myasthenia Gravis (MG) varied from 150 to 200 cases per million. In earlier years, the prevalence of MG was estimated to be 1 in 20,000, which then rose to 1 in 17,000 after the finding of AChR antibodies in 1969. Nevertheless, the mortality rate of the disease is still in the range of 5 and 9 percent and is a bit greater in men than in women. A strong emphasis on introducing new therapies and improving healthcare infrastructure is expanding the market growth.

Key Developments

In May 2022, UK Early Access was Granted for Argenx's generalized myasthenia gravis treatment.